Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Oct;79(10):1060-1078.
doi: 10.1055/a-0919-4959. Epub 2019 Jul 16.

Diagnosis, Therapy and Follow-up of Vaginal Cancer and Its Precursors. Guideline of the DGGG and the DKG (S2k-Level, AWMF Registry No. 032/042, October 2018)

Hans-Georg Schnürch  1 , Sven Ackermann  2 , Celine D Alt-Radtke  3 , Lukas Angleitner  4 , Jana Barinoff  5 , Matthias W Beckmann  6 , Carsten Böing  7 , Christian Dannecker  8 , Tanja Fehm  9 , Rüdiger Gaase  10 , Paul Gass  6 , Marion Gebhardt  11 , Friederike Gieseking  12 , Andreas Günthert  13 , Carolin C Hack  6 , Peer Hantschmann  14 , Lars Christian Horn  15 , Martin C Koch  6 , Anne Letsch  16 , Peter Mallmann  17 , Bernhard Mangold  18 , Simone Marnitz  19 , Grit Mehlhorn  20 , Kerstin Paradies  21 , Michael J Reinhardt  22 , Reina Tholen  23 , Uwe Torsten  24 , Wolfgang Weikel  25 , Linn Wölber  26 , Monika Hampl  9
Affiliations

Diagnosis, Therapy and Follow-up of Vaginal Cancer and Its Precursors. Guideline of the DGGG and the DKG (S2k-Level, AWMF Registry No. 032/042, October 2018)

Hans-Georg Schnürch et al. Geburtshilfe Frauenheilkd. 2019 Oct.

Abstract

Purpose This is an official guideline, published and coordinated by the Gynecological Oncology Working Group (AGO) of the German Cancer Society (DKG) and the German Society for Gynecology and Obstetrics (DGGG). Vaginal cancers are rare tumors, which is why there is very little evidence on these tumors. Knowledge about the optimal clinical management is limited. This first German S2k guideline on vaginal cancer has aimed to compile the most current expert knowledge and offer new recommendations on the appropriate treatment as well as providing pointers about individually adapted therapies with lower morbidity rates than were previously generally available. The purpose of this guideline is also to set up a register to record data on treatment data and the course of disease as a means of obtaining evidence in future. Methods The present S2k guideline was developed by members of the Vulvar und Vaginal Tumors Commission of the AGO in an independently moderated, structured, formal consensus process and the contents were agreed with the mandate holders of the participating scientific societies and organizations. Recommendations To optimize the daily care of patients with vaginal cancer: 1. Monitor the spread pattern; 2. Follow the step-by-step diagnostic workup based on initial stage at detection; 3. As part of individualized clinical therapeutic management of vaginal cancer, follow the sentinel lymph node protocol described here, where possible; 4. Participate in the register study on vaginal cancer.

Keywords: VaIN; sentinel lymph node biopsy; vaginal cancer.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest/Interessenkonflikt The conflicts of interests of the authors are listed in the long version of the guideline./Die Interessenkonflikte der Autoren sind in der Langfassung der Leitlinie aufgelistet.

Figures

Fig. 1
Fig. 1
Flowchart for the diagnostic workup and treatment of vaginal carcinoma with the option of carrying out a sentinel LN procedure or not. [rerif]
Abb. 1
Abb. 1
Ablaufschema für die Diagnostik und Therapie des Vaginalkarzinoms unter fakultativer Einbeziehung des Sentinel-LK-Verfahrens. [rerif]
See this image and copyright information in PMC

References

    1. Schubert-Fritschle G, Schlesinger-Raab A, Engel J. 2. Aufl. München: Zuckschwerdt Verlag; 2011. Malignome der Vulva und Vagina.
    1. Lilic V, Lilic G, Filipovic S. Primary carcinoma of the vagina. J BUON. 2010;15:241–247. - PubMed
    1. Melnick S, Cole P, Anderson D. Rates and risks of diethylstilbestrol-related clear-cell adenocarcinoma of the vagina and cervix. An update. N Engl J Med. 1987;316:514–516. - PubMed
    1. Ries L AG, Young J L, Keel G E, Eisner M P, Lin Y D, Horner M J. SEER Survival Monograph: Cancer Survival among Adults: U.S. SEER Program, 1988 – 2001, Patient and Tumor Characteristics. National Cancer Institute, SEER Program, NIH Pub. No. 07-6215, Bethesda, MD: NIH. 2007.
    1. Madsen B S, Jensen H L, van den Brule A J. Risk factors for invasive squamous cell carcinoma of the vulva and vagina–population-based case-control study in Denmark. Int J Cancer. 2008;122:2827–2834. - PubMed